# Rationale for the numbers

**P(grant) = 0.38. Predicted disposition: denied.**

## Inputs read

- Snapshot `record/snapshots/2026-06-23.json` (mode `forward`, cut kind `date`, cutoff 2026-06-23). It shows: docketed Feb 24, 2026; State waived response Mar 16; distributed for the Apr 17 conference; one amicus (X.AI, LLC, by Clement & Murphy); Response Requested Mar 30; BIO filed May 28; petitioner waived the 14-day wait; redistributed for the Jun 18 conference with the reply; CVSG on Jun 22. Two distributions, CVSG on the docket.
- `record/context.json`: band `high` under `sal-v4`, `distribution_count` 2, `cvsg_date` 2026-06-22, Term 2025, `signals_observable` true.
- `record/documents/`: `questions-presented.txt`, `petition.txt` (44 pp., full text), `brief-in-opposition.txt` (27 pp., full text). None flagged `empty_text`. I read the petition and the BIO in full.
- `metrics/statpack.md`: the modern-cert disposition table, the relist and CVSG cuts (paid scored segment), and the sal-v4 band table.
- Live check (forward mode): the CourtListener docket record (last modified June 22, 2026, not terminated) and the supremecourt.gov docket page, which lists no entry after the June 22 CVSG. The petition is genuinely pending and the SG has not filed, so the cell is correctly provisioned.

## Anchor

The band table's heading is `sal-v4` and matches the context's `salience_version`, so the anchor is the `high` band's bracketed `reached` rate pooled over Terms strictly before 2025. The table renders 2017 through 2024 as prior rows; pooling them:

| Pool | grants (weighted) | n | rate |
| --- | --: | --: | --: |
| high band, reached, OT2017–OT2024 | 313.9 | 898 | 35.0% |

The CVSG cut says the same thing from the other direction: among paid petitions with a CVSG, granted 29.4% + gvr 5.5% = 34.9% any-grant, denied 62.0%. For comparison, petitions with two relists show 27.8% granted + 13.1% gvr, but that bucket is a terminal count and this petition will be distributed at least once more, so I do not anchor on it. Anchor: roughly 0.35.

## Adjustments

Upward:

- Two escalation steps, not one. The Court called for a response after the State waived, then issued the CVSG at the second conference with a full BIO and reply in hand. The CVSG is priced into the anchor; the earlier Response Requested is a modest extra signal that several Justices were interested before the State said anything.
- The Ninth Circuit's opinion is published, reverses a district court judgment for the challenger, and drew a dissent (Judge Bea) on the First Amendment question. The majority announced a categorical treatment of "product-specific government reporting requirements" as commercial speech, which is the kind of new tier NIFLA criticized. The petition's framing of Question 1 is close to how the Court itself would frame it.
- Elite petitioner-side counsel (Arnold & Porter, Allon Kedem, counsel of record) and a well-resourced trade-association petitioner. The reply was filed the day of redistribution and the 14-day wait was waived, which reads as a petitioner pressing for a decision this Term.
- Recurring national issue: many states have drug-price transparency statutes with reporting and posting features, and the compelled-disclosure question extends beyond pharma (the X.AI amicus signals the technology sector's interest in AI and content-moderation disclosure mandates).
- Justices Thomas and Kavanaugh have prior writings hostile to exactly the "information asymmetry" rationale the panel adopted.

Downward:

- The SG is the pivot, and I lean toward a denial recommendation. The federal government administers vast mandatory-reporting regimes and has itself pursued drug-price transparency. A brief that defends reporting requirements under intermediate scrutiny and calls the panel's ruling a fact-bound Bolger application is the natural institutional position. Roughly: P(SG recommends grant) about 0.30 to 0.35; P(grant | SG grant) about 0.75 to 0.80; P(grant | SG deny) about 0.10 to 0.15. That arithmetic lands at 0.30 to 0.37 before the case-specific pluses above.
- The BIO's vehicle points have force. The challenge is facial, and Moody v. NetChoice (majority and the Barrett concurrence) has made the Court wary of facial First Amendment challenges. The district court itself classified the reports as commercial speech, so the classification question may not change the outcome if the Court would apply intermediate scrutiny with more rigor. The takings claim is unanimous below, rests on Ruckelshaus v. Monsanto, and carries an unresolved ripeness question on a permissive disclosure provision that has never been invoked.
- The asserted circuit split is soft. Amestoy (2d Cir. 1996) is old and often confined; American Meat Institute upheld the disclosure it reviewed; the Second, Fourth, Seventh, Eleventh and Sixth Circuit cases cited on the Bolger factors did not involve reports to regulators. This is the first appellate decision on a First Amendment challenge to a drug-price transparency statute, so the Court may prefer to wait for a second circuit.
- Only one amicus brief at the cert stage is thin for a case pitched as economy-wide.

Net: the pluses and minuses are roughly balanced around the anchor, with a slight upward tilt because the record shows the Court itself has already escalated twice on this petition. I land at 0.38.

## Other claims

- `disposition` 0.38: same belief as `probability`.
- `relist-increment` 0.97: a CVSG'd petition is always redistributed after the SG files; the residual is dismissal or withdrawal before that happens, which is rare.
- `cvsg-increment` 0.02: a CVSG is already on the docket, so the harness masks this claim as vacuous; I state a near-zero probability of a second invitation.
- `summary-disposition-route` 0.08 (conditional on grant): the CVSG cut's GVR share of the grant family is about 16%, but a GVR needs an intervening decision to remand in light of, and I know of none bearing on compelled reporting; a case carried through Response Requested and a CVSG is set for argument if taken. I sit well below the cut's share.
- `dissent-from-denial` 0.20 (conditional on denial): plausible writers exist (Thomas, Kavanaugh, possibly Gorsuch), the issue is one they have written on, and the case was CVSG'd, but most denials following an SG denial recommendation are silent.

## Big case score 0.62

Stakes if decided are substantial: the scrutiny tier for compelled government reporting requirements would govern state drug-price transparency laws nationwide and the broader wave of narrative disclosure mandates (ESG, AI, content moderation). It is not a top-tier case: the likely holding would be a remand on the correct framework rather than a final ruling on HB 4005, and the takings question is unlikely to be reached.

## Where to discount me

- The largest uncertainty is the SG's position, which will not be known until late 2026. My lean toward a denial recommendation is an inference from institutional interests, not from anything on the record. If the SG recommends a grant on Question 1, my number is too low by roughly half.
- The corpus prior retrieval (`fedcourts query`) returned mainly emergency-application rows despite the documented screen for non-cert forms, so it contributed no comparable CVSG'd cert priors; the statpack tables carried the quantitative anchoring.
- The docket carries no signal about which Justices favored the CVSG; I have inferred interest from the two escalation steps only.
